TOWER
The freeze period of Yes Bank has got over and its share price has come down, which provides an excellent opportunity to add this potential multi-bagger. Buy and hold for two years.
TGV SRAAC posted 9M EPS of Rs 30.81 against Rs 6.14 YoY and may post FY23EPS of Rs 42. It trades at a PE of just 2.61x against the industry average of 47x and a PB ratio of just 1.05x against industry average of 8.72x. Stock is poised to give surprising returns in FY24. Buy.
JK Tyres has made a QIP allotment of CCD worth Rs.240 cr. to IFC to fund its expansion plans. Its profitability is on the rise. Buy.
Praveg has secured a work order for the development, operation, maintenance, and management of a Tent City at Diu. Accumulate.
Kirloskar Ferrous has completed the installation of HPML at the Solapur plant worth Rs.170 cr. Add.
The USFDA has cleared the Granules India’s step-down subsidiary in the consumer and hygiene business spread over 79000 sq ft in US. It is constantly reporting better profits. Add.
The soaring volumes on the counter of Aarti Drugs is a pointer to some good news in the coming weeks. Risk-bearing investors may add.
Ahluwalia Contracts has bagged a hospital construction contract in Mumbai for Rs.723+ cr.
The recent slide in volumes and prices of shares across the board could not dent the price of Hari Om Pipes. There is definitely some good news in the offing. Add.
In spite of severe pressure on the entire banking sector, Karnataka Bank has stood out tall. The current working is suggestive of a big breakout. Add for the long term.
Polyplex Corporation price has been dragged from a year high of Rs.2870 to Rs.1274. It has an EPS of Rs.168 and a P/BV of 0.75x and is available at a P/E of just 7.54x. Buy for the long term.
Adani Enterprises promoted Adani Petrochemical project of PVC from Coal is suspended and the fundraising of around Rs.34000 cr. Stay away till the dust finally settles.
GNFC is the sole manufacturer of Aniline and caters to 31% of the Indian markets. Add on dips.
The promoters of Marksans Pharma are buying its shares, which indicates that it is poised for better times ahead. Accumulate.
.
The freeze period of Yes Bank has got over and its share price has come down, which provides an excellent opportunity to add this potential multi-bagger. Buy and hold for two years.
TGV SRAAC posted 9M EPS of Rs 30.81 against Rs 6.14 YoY and may post FY23EPS of Rs 42. It trades at a PE of just 2.61x against the industry average of 47x and a PB ratio of just 1.05x against industry average of 8.72x. Stock is poised to give surprising returns in FY24. Buy.
JK Tyres has made a QIP allotment of CCD worth Rs.240 cr. to IFC to fund its expansion plans. Its profitability is on the rise. Buy.
Praveg has secured a work order for the development, operation, maintenance, and management of a Tent City at Diu. Accumulate.
Kirloskar Ferrous has completed the installation of HPML at the Solapur plant worth Rs.170 cr. Add.
The USFDA has cleared the Granules India’s step-down subsidiary in the consumer and hygiene business spread over 79000 sq ft in US. It is constantly reporting better profits. Add.
The soaring volumes on the counter of Aarti Drugs is a pointer to some good news in the coming weeks. Risk-bearing investors may add.
Ahluwalia Contracts has bagged a hospital construction contract in Mumbai for Rs.723+ cr.
The recent slide in volumes and prices of shares across the board could not dent the price of Hari Om Pipes. There is definitely some good news in the offing. Add.
In spite of severe pressure on the entire banking sector, Karnataka Bank has stood out tall. The current working is suggestive of a big breakout. Add for the long term.
Polyplex Corporation price has been dragged from a year high of Rs.2870 to Rs.1274. It has an EPS of Rs.168 and a P/BV of 0.75x and is available at a P/E of just 7.54x. Buy for the long term.
Adani Enterprises promoted Adani Petrochemical project of PVC from Coal is suspended and the fundraising of around Rs.34000 cr. Stay away till the dust finally settles.
GNFC is the sole manufacturer of Aniline and caters to 31% of the Indian markets. Add on dips.
The promoters of Marksans Pharma are buying its shares, which indicates that it is poised for better times ahead. Accumulate.
.
Comments
Post a Comment